Trial Profile
Phase-III Study of Standard Radiotherapy Plus Concomitant and Adjuvant Nimotuzumab Plus Temozolomide vs. Standard Radiotherapy Plus Concomitant and Adjuvant Temozolomide in Patient With Newly Diagnosed, Histologically Confirmed Glioblastoma Multiforme Grade IV
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- Sponsors Oncoscience
- 05 Jun 2012 Final results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
- 23 Sep 2011 Final results to be reported in the second half of 2011, after completion of a biomarker correlation study, according to a YM BioSciences media release
- 08 Jun 2011 Additional lead trial centres added as reported by ClinicalTrials.gov.